Subsidiaries
Livzon Microsphere Technology Co., Ltd.
The Livzon Pharmaceutical Group founded the Chemical Research Institute Microsphere Workshop in January 2013. In March 2015, the National-Local Joint Engineering Research Center of Long-acting Microsphere Technology was established.
Livzon Microsphere Technology Co., Ltd. was founded on July 3, 2017. It is one of the earliest enterprises in China engaged in the R&D of microsphere products. Currently there are 6 projects in different phases of research. The project Triptorelin (release period: 1 month) has entered the clinical trial phase, Leuprorelin (release period: 3 months) has been approved for clinical practice, and the other 4 projects are at the pilot scale experiment stage.
The company was supported by global talent-hunting project named 2016 Guangdong “Pearl River Talents Plan” for the recruitment of the innovative and entrepreneurial teams. In 2016 and 2017, the company was supported by the Special Project on the Industrialization of Major Scientific and Technological Achievements. It was also supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” in 2017.
Leuprorelin Acetate Microspheres for Injection, which is used to treat endometriosis and uterine fibroids, is one of the first microsphere preparations that was sold on the national market.
The company’s objective is to build an advanced and world leading platform integrating the R&D of microsphere preparation.